On the stock market since 2014, it operates in the world of health and science. It has 101 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $31.1M a year. A small number, but proof the product has real buyers.
There is $394.3M in the vault; even if every debt were paid off, $279.8M would remain.
A loss of $105.4M against $31.1M in annual sales.
Over the last 12 months, executives reported 226 sells against just 74 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, CBAY sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: CBAY is a high-risk stock — not yet profitable, and its future rides on its product catching on.